Ibrahima Soumaoro

Ibrahima Soumaoro

Genmab - / Denmark
Medical and Health Sciences / Medical Oncology
AD Scientific Index ID: 4970998
person_outline Ibrahima Soumaoro's MOST POPULAR ARTICLES
1-) Safety and efficacy of nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: results from the phase I/II CheckMate 358 trial RW Naumann, A Hollebecque, T Meyer, MJ Devlin, A Oaknin, J Kerger, ... Journal of Clinical Oncology 37 (31), 2825, 2019 2262019
2-) An open-label, multicohort, phase I/II study of nivolumab in patients with virus-associated tumors (CheckMate 358): Efficacy and safety in recurrent or metastatic (R/M … A Hollebecque, T Meyer, KN Moore, JPH Machiels, J De Greve, ... Journal of Clinical Oncology, 2017 1092017
3-) Abstract CT074: Non-comparative, open-label, multiple cohort, phase 1/2 study to evaluate nivolumab (NIVO) in patients with virus-associated tumors (CheckMate 358): Efficacy …SL Topalian, S Bhatia, A Hollebecque, A Awada, JPD Boer, ...Cancer Research 77 (13_Supplement), CT074-CT074, 2017912017
4-) Non-comparative, open-label, multiple cohort, phase 1/2 study to evaluate nivolumab (NIVO) in patients with virus-associated tumors (CheckMate 358): efficacy and safety in …SL Topalian, S Bhatia, A Hollebecque, A Awada, JP De Boer, ...Cancer Research 77, 2017752017
5-) Nivolumab (nivo) as neoadjuvant therapy in patients with resectable Merkel cell carcinoma (MCC) in CheckMate 358.SL Topalian, S Bhatia, RR Kudchadkar, A Amin, WH Sharfman, C Lebbe, ...Journal of Clinical Oncology 36 (15_suppl), 9505-9505, 2018502018